Oruka Therapeutics, Inc. Logo

Oruka Therapeutics, Inc.

Develops novel biologics for chronic skin diseases and inflammatory conditions.

ORKA | US

Overview

Corporate Details

ISIN(s):
US6876041087 (+1 more)
LEI:
Country:
United States of America
Address:
855 OAK GROVE AVE., 94025 MENLO PARK

Description

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-20 00:56 English 12.4 KB
2025-09-19 23:33
OWNERSHIP DOCUMENT
English 8.7 KB
2025-08-11 22:29
PROSPECTUS SUPPLEMENT
English 229.0 KB
2025-08-11 22:01
QUARTERLY REPORT
English 1.4 MB
2025-07-18 02:12 English 12.6 KB
2025-07-02 03:26
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.1 KB
2025-07-02 03:21
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
English 11.9 KB
2025-07-01 22:01
CURRENT REPORT
English 165.7 KB
2025-06-03 22:30
OWNERSHIP DOCUMENT
English 9.0 KB
2025-06-03 22:14
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.2 KB
2025-06-03 22:13
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.1 KB
2025-06-03 22:13
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.2 KB
2025-06-03 22:10
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.1 KB
2025-06-03 22:00
CURRENT REPORT
English 69.2 KB
2025-05-15 14:00 English 175.1 KB

Automate Your Workflow. Get a real-time feed of all Oruka Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oruka Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oruka Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.